Jump to content

AI-10-49

Add links
From Wikipedia, the free encyclopedia
AI-10-49
Identifiers
  • 2,2'-(5,5'-((Oxybis(ethane-2,1-diyl))bis(oxy))bis(pyridine-5,2-diyl))bis(5-(trifluoromethoxy)-1H-benzo[d]imidazole)
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC30H22F6N6O5
Molar mass660.533 g·mol−1
3D model (JSmol)
  • FC(F)(F)OC1=CC2=C(C=C1)NC(C(C=C3)=NC=C3OCCOCCOC(C=C4)=CN=C4C5=NC6=CC(OC(F)(F)F)=CC=C6N5)=N2
  • InChI=1S/C30H22F6N6O5/c31-29(32,33)46-17-1-5-21-25(13-17)41-27(39-21)23-7-3-19(15-37-23)44-11-9-43-10-12-45-20-4-8-24(38-16-20)28-40-22-6-2-18(14-26(22)42-28)47-30(34,35)36/h1-8,13-16H,9-12H2,(H,39,41)(H,40,42)
  • Key:WJBSSBFGPKTMQQ-UHFFFAOYSA-N

AI-10-49 is a small molecule inhibitor of leukemic oncoprotein CBFβ-SMHHC developed by the laboratory of John Bushweller (University of Virginia) with efficacy demonstrated by the laboratories of Lucio H. Castilla (University of Massachusetts Medical School) and Monica Guzman (Cornell University).[1][2][3][4] AI-10-49 allosterically binds to CBFβ-SMMHC and disrupts protein-protein interaction between CBFβ-SMMHC and tumor suppressor RUNX1. This inhibitor is under development as an anti-leukemic drug.

Core binding factors

[edit]

Core-binding factor (CBF) is a heterodimeric transcription factor composed by the CBFβ and RUNX subunits (the latter is encoded by RUNX1, RUNX2, or RUNX3 genes). CBF plays critical roles in most hematopoietic lineages, regulating gene expression of a variety of genes associated with cell cycle, differentiation, signaling and adhesion.[5] In hematopoiesis, CBF regulates progenitor cell fate decisions and differentiation at multiple levels. The function of CBF is essential for the emergence of embryonic hematopoietic stem cells (HSCs) and establishment of definitive hematopoiesis at midgestation.[6][7][8] Similarly, in adult hematopoiesis, CBF regulates the frequency and differentiation of HSCs, lymphoid and myeloid progenitors,[9][10] establishing CBF as a master regulator of hematopoietic homeostasis.

Core binding factors and leukemia

[edit]

CBF members are frequent targets of mutations and rearrangements in human leukemia. Point-mutations in RUNX1 gene have been reported in patients with familial platelet disorder, myeloid dysplastic syndrome, and chronic myelomonocytic leukemia.[11][12] In addition, RUNX1 mutations have also been reported in Acute myeloid leukemia (AML).[13] The RUNX1 and CBFB genes are targets of chromosome rearrangements that create oncogenic fusion genes in leukemia. The chromosome translocation t(12;21) (p13.1;q22) causes the fusion of the ETS variant 6 (ETV6) and RUNX1 genes results in ETV6-RUNX1 gene fusion and is the most common genetic aberration in childhood acute lymphoblastic leukemia (ALL).[14] The "core binding factor AML" (CBF AML) [WHO classification] is the most common group of AML, including groups with the chromosome rearrangements inv(16)(p13q22) and t(8;21)(q22;q22). The chromosome translocation t(8;21)(q22;q22) creates the RUNX1-ETO fusion gene, which is expressed in FAB subtype M2 AML samples.[15] The pericentric chromosome inversion inv(16)(p13q22) creates the CBFB-MYH11 fusion gene, which encodes the CBFβ-SMMHC fusion protein.[16][17]

Inv(16) leukemia

[edit]

The inv(16) is present in all M4Eo subtype AML, representing one of the most common change in AML, and accounting for ≈12% of de novo human AML.[18] Studies by various laboratories have established that CBFβ-SMMHC acts as a dominant repressor of CBF function in vivo and specifically blocks lymphoid and myeloid lineage differentiation.[19][20][21][22]

Treatment of AML varies based on the prognosis and mutations identified in the patient sample. Current treatment for inv(16) AML uses chemotherapy drugs, such as doxorubicin and cytarabine, with an estimated 5-year overall survival of 60% in young patients and only 20% in the elderly.[23][24]

Discovery

[edit]

CBFβ-SMMHC outcompetes CBFβ for binding to RUNX1 by direct protein-protein interaction.[25][26][27]

Using a fluorescence resonance energy transfer (FRET) based assay, AI-4-57 was discovered as the lead compound which can inhibit CBFβ-SMHHC –RUNX1 protein-protein interaction.[1] To get good in vivo pharmacokinetics, selectivity and potency AI-10-49 was developed which has a seven atom polyethylene glycol-based linker and a trifluoromethoxy substitution. This molecule releases RUNX1 from CBFβ-SMHHC specifically and restores the RUNX1 transcriptional program in inv(16) positive human leukemic cells. Viability assays showed AI-10-49 has an IC50 of 0.6μM. Pharmacokinetic studies showed that AI-10-49 has half-life of 380 minutes in mouse plasma. AI-10-49 prolonged the survival of mice transplanted with CBFβ-SMHHC leukemic cells without any signs of toxicity. AI-10-49 reduced viability and colony forming ability of human primary inv(16) leukemic blast cells, without affecting normal human bone marrow cells as wells non- inv(16) primary human leukemic blast cells. Overall, these findings validate inhibition of RUNX1- CBFβ-SMMHC protein-protein interaction as a novel therapeutic avenue for leukemia with inv(16) and AI-10-49 as a specific inhibitor of CBFβ-SMHHC oncoprotein. The discovery of AI-10-49 provides additional evidence that transcription factor drivers of cancer can be directly targeted. AI-10-49 belongs to a select group of protein-protein interaction inhibitors that has been shown to have specific and potent efficiency without toxicity in cancer therapy.[citation needed]

Mechanism of action of AI-10-49

[edit]

The mechanism of action of AI-10-49 was recently elucidated by the Castilla laboratory at University of Massachusetts Medical School.[28][29][30][31] Gene Set Enrichment Analysis of RNA-seq data from inv(16) AML cells treated with AI-10-49 identified the deregulation of a MYC signature, including cell cycle, ribosome biogenesis and metabolism. MYC shRNA knockdown induced apoptosis of inv(16) AML cells, and MYC overexpression partially rescued AI-10-49 induced apoptosis. Furthermore, mouse leukemia cells transduced with Myc shRNAs showed significant delay in leukemic latency upon transplantation, validating the requirement of MYC in inv(16) AML maintenance in vivo. Pharmacologic inhibition of MYC activity, using a combined treatment with AI-10-49 and the BET-family bromodomain inhibitor JQ1, revealed a strong synergy in inv(16) AML cells and a significant delay in leukemia latency in mice. ChIP-seq and ATAC-seq analysis revealed that inhibition of the CBFβ-SMHHC–RUNX1 protein–protein interaction by AI-10-49 results in increased RUNX1 occupancy at three MYC distal enhancers downstream from MYC transcription start site. Deletion of the RUNX1 binding site in these enhancers by genome editing (CRISPR/Cas9) reduced MYC transcript levels and the viability of inv(16) AML cells, indicating that each one of these enhancers plays a critical role in regulating MYC levels and sustaining the survival of inv(16) AML cells. Analysis of enhancer-promoter interactions by chromosome conformation capture carbon copy (5C) in inv(16) AML cells revealed that the three enhancers are physically connected with each other and to the MYC promoter. Analysis of chromatin immunoprecipitation revealed that AI-10-49 treatment results in the displacement of the SWI/SNF complex component BRG1 and RUNX1 mediated recruitment of polycomb-repressive complex 1 (PRC1) component RING1B at the three MYC enhancers. Taken together, these results demonstrate that AI-10-49 treatment induces an acute release of RUNX1, increases RUNX1 occupancy at MYC enhancers, and disrupts enhancer chromatin dynamics which in turn induces apoptosis by repressing MYC. Furthermore, this study suggests that combined treatment of inv(16) AML with AI-10-49 and BET-family inhibitors may represent a promising targeted therapy.[citation needed]

Protein-protein interaction inhibitors in cancer therapy

[edit]

Targeting protein-protein interaction with small molecule is known to be extremely difficult due to the fact that binding regions consist of wide, shallow surfaces.[32] There are few protein-protein interaction inhibitors with specific and non-toxic effect in various cancer types. The first and best characterized protein-protein interaction inhibitor in cancer therapy is Nutlin.[33] Nutlin inhibits the interaction between HDM2 and tumour suppressor p53. After the discovery of Nutlin, more than 20 small molecule inhibitors have been developed by academic institutes and pharmaceutical companies of which 8 inhibitors are under Phase 1 clinical trials.[34] Other examples for protein-protein interaction inhibitors include JQ1 (inhibits the interaction between acetylated histones and BRD4);[35] 79-6 (inhibits BCL6 BTB domain dimerization);[36] MI-463 and MI-503 (inhibit Menin-MLL interaction)[37] and ABT-737 (inhibits BCL2L1-BCL2 interaction).[38]

References

[edit]
  1. ^ a b Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, et al. (February 2015). "Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice". Science. 347 (6223): 779–784. doi:10.1126/science.aaa0314. PMC 4423805. PMID 25678665.
  2. ^ Chen A, Koehler AN (February 2015). "Drug discovery. Tying up a transcription factor". Science. 347 (6223). New York, N.Y.: 713–4. doi:10.1126/science.aaa6119. PMID 25678644. S2CID 20025135.
  3. ^ Miura G (April 2015). "Free RUNX1". Nature Chemical Biology. 11 (4): 241. doi:10.1038/nchembio.1784.
  4. ^ Pulikkan JA, Illendula A, Grembecka J, Xue L, Rajewski R, Guzman ML, et al. (November 2014). "Selective inhibition of the leukemia fusion protein CBFβ-SMMHC by small molecule AI-10-49 in the treatment of Inv (16) AML". Blood. 124 (21): 390. doi:10.1182/blood.V124.21.390.390.
  5. ^ Blyth K, Cameron ER, Neil JC (May 2005). "The RUNX genes: gain or loss of function in cancer". Nature Reviews. Cancer. 5 (5): 376–87. doi:10.1038/nrc1607. PMID 15864279. S2CID 335980.
  6. ^ Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR (January 1996). "AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis". Cell. 84 (2): 321–30. doi:10.1016/s0092-8674(00)80986-1. PMID 8565077. S2CID 14180316.
  7. ^ de Bruijn MF, Speck NA, Peeters MC, Dzierzak E (June 2000). "Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo". The EMBO Journal. 19 (11): 2465–74. doi:10.1093/emboj/19.11.2465. PMC 212758. PMID 10835345.
  8. ^ Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA (February 2009). "Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter". Nature. 457 (7231): 887–91. Bibcode:2009Natur.457..887C. doi:10.1038/nature07619. PMC 2744041. PMID 19129762.
  9. ^ Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, et al. (March 2004). "AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis". Nature Medicine. 10 (3): 299–304. doi:10.1038/nm997. PMID 14966519. S2CID 29313356.
  10. ^ Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, et al. (July 2005). "Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype". Blood. 106 (2): 494–504. doi:10.1182/blood-2004-08-3280. PMC 1895175. PMID 15784726.
  11. ^ Buijs A, Poddighe P, van Wijk R, van Solinge W, Borst E, Verdonck L, et al. (November 2001). "A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies". Blood. 98 (9): 2856–2858. doi:10.1182/blood.v98.9.2856. PMID 11675361.
  12. ^ Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. (October 1999). "Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia". Nature Genetics. 23 (2): 166–175. doi:10.1038/13793. PMID 10508512. S2CID 33348053.
  13. ^ Silva FP, Lind A, Brouwer-Mandema G, Valk PJ, Giphart-Gassler M (August 2007). "Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients". Haematologica. 92 (8): 1123–1126. doi:10.3324/haematol.11296. PMID 17650443.
  14. ^ Pui CH, Relling MV, Downing JR (April 2004). "Acute lymphoblastic leukemia". The New England Journal of Medicine. 350 (15): 1535–48. doi:10.1056/NEJMra023001. PMID 15071128.
  15. ^ Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, et al. (October 1992). "Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt". Blood. 80 (7): 1825–1831. doi:10.1182/blood.V80.7.1825.1825. PMID 1391946.
  16. ^ Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD (September 1983). "Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association". The New England Journal of Medicine. 309 (11): 630–636. doi:10.1056/NEJM198309153091103. PMID 6577285.
  17. ^ Liu P, Tarlé SA, Hajra A, Claxton DF, Marlton P, Freedman M, et al. (August 1993). "Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia". Science. 261 (5124): 1041–1044. Bibcode:1993Sci...261.1041L. doi:10.1126/science.8351518. PMID 8351518.
  18. ^ Look AT (November 1997). "Oncogenic transcription factors in the human acute leukemias". Science. 278 (5340). New York, N.Y.: 1059–64. doi:10.1126/science.278.5340.1059. PMID 9353180.
  19. ^ Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M, et al. (November 1996). "Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11". Cell. 87 (4): 687–696. doi:10.1016/s0092-8674(00)81388-4. PMID 8929537. S2CID 11330417.
  20. ^ Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, et al. (October 1999). "The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia". Nature Genetics. 23 (2): 144–146. doi:10.1038/13776. PMID 10508507. S2CID 7801459.
  21. ^ Kuo YH, Landrette SF, Heilman SA, Perrat PN, Garrett L, Liu PP, et al. (January 2006). "Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia". Cancer Cell. 9 (1): 57–68. doi:10.1016/j.ccr.2005.12.014. PMID 16413472.
  22. ^ Kuo YH, Gerstein RM, Castilla LH (February 2008). "Cbfbeta-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B-cell development". Blood. 111 (3): 1543–1551. doi:10.1182/blood-2007-07-104422. PMC 2214760. PMID 17940206.
  23. ^ Marcucci G, Mrózek K, Bloomfield CD (January 2005). "Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics". Current Opinion in Hematology. 12 (1): 68–75. doi:10.1097/01.moh.0000149608.29685.d1. PMID 15604894. S2CID 6183391.
  24. ^ Farag SS, Archer KJ, Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, et al. (July 2006). "Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461". Blood. 108 (1): 63–73. doi:10.1182/blood-2005-11-4354. PMC 1895823. PMID 16522815.
  25. ^ Lukasik SM, Zhang L, Corpora T, Tomanicek S, Li Y, Kundu M, et al. (September 2002). "Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis". Nature Structural Biology. 9 (9): 674–9. doi:10.1038/nsb831. PMID 12172539. S2CID 29619401.
  26. ^ Adya N, Stacy T, Speck NA, Liu PP (December 1998). "The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates". Molecular and Cellular Biology. 18 (12): 7432–43. doi:10.1128/MCB.18.12.7432. PMC 109324. PMID 9819429.
  27. ^ Huang G, Shigesada K, Wee HJ, Liu PP, Osato M, Ito Y (April 2004). "Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera". Blood. 103 (8): 3200–7. doi:10.1182/blood-2003-07-2188. PMID 15070703.
  28. ^ Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, et al. (June 2018). "CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia". Cell. 174 (1): 172–186.e21. doi:10.1016/j.cell.2018.05.048. PMC 6211564. PMID 29958106.
  29. ^ Pulikkan JA, Hegde M, Belaghzal H, Illendula A, Yu J, Ahmed H, et al. (December 2017). "CBFβ-SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv (16) Leukemia". Blood. 130: 784. doi:10.1182/blood.V130.Suppl_1.784.784.
  30. ^ Kotsantis P, Petermann E, Boulton SJ (May 2018). "Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place". Cancer Discovery. 8 (5): 537–555. doi:10.1158/2159-8290.CD-17-1461. PMC 5935233. PMID 29653955.
  31. ^ Potluri S, Coleman D, Bonifer C (2018). "Pharmacological inhibition of aberrant transcription factor complexes in inversion 16 acute myeloid leukemia". Stem Cell Investigation. 5: 30. doi:10.21037/sci.2018.09.03. PMC 6182015. PMID 30363728.
  32. ^ Wells JA, McClendon CL (December 2007). "Reaching for high-hanging fruit in drug discovery at protein-protein interfaces". Nature. 450 (7172): 1001–9. Bibcode:2007Natur.450.1001W. doi:10.1038/nature06526. PMID 18075579. S2CID 205211934.
  33. ^ Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (February 2004). "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science. 303 (5659): 844–848. Bibcode:2004Sci...303..844V. doi:10.1126/science.1092472. PMID 14704432. S2CID 16132757.
  34. ^ Khoo KH, Hoe KK, Verma CS, Lane DP (March 2014). "Drugging the p53 pathway: understanding the route to clinical efficacy". Nature Reviews. Drug Discovery. 13 (3): 217–36. doi:10.1038/nrd4236. PMID 24577402. S2CID 31000448.
  35. ^ Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. (December 2010). "Selective inhibition of BET bromodomains". Nature. 468 (7327): 1067–1073. Bibcode:2010Natur.468.1067F. doi:10.1038/nature09504. PMC 3010259. PMID 20871596.
  36. ^ Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. (April 2010). "A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo". Cancer Cell. 17 (4): 400–411. doi:10.1016/j.ccr.2009.12.050. PMC 2858395. PMID 20385364.
  37. ^ Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. (April 2015). "Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo". Cancer Cell. 27 (4): 589–602. doi:10.1016/j.ccell.2015.02.016. PMC 4415852. PMID 25817203.
  38. ^ Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. (June 2005). "An inhibitor of Bcl-2 family proteins induces regression of solid tumours". Nature. 435 (7042): 677–681. Bibcode:2005Natur.435..677O. doi:10.1038/nature03579. PMID 15902208. S2CID 4335635.
Retrieved from "https://en.wikipedia.org/w/index.php?title=AI-10-49&oldid=1186068470"